HER2-Low Breast Cancer: a New Subtype?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Link
https://link.springer.com/content/pdf/10.1007/s11864-023-01068-1.pdf
Reference34 articles.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. https://doi.org/10.3322/caac.21590.
2. Corti C, Giugliano F, Nicolò E, Ascione L, Curigliano G. Antibody–drug conjugates for the treatment of breast cancer. Cancers. 2021;13:2898.
3. Eiger D, Agostinetto E, Saúde-Conde R, de Azambuja E. The exciting new field of HER2-low breast cancer treatment. Cancers (MDPI). 2021;13. https://doi.org/10.3390/cancers13051015.
4. Gennari A, André F, Barrios C, Cortes J, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021. https://doi.org/10.1016/j.annonc.2021.09.019. Most recent clinical practice guidelines for the treatment of breast cancer, provided by the European Society for Medical Oncology.
5. Wolff AC, Hammond MEH, Allison KH, Harvey BE, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105–22. https://doi.org/10.1200/JCO.2018.77.8738.
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. KIF18B: an important role in signaling pathways and a potential resistant target in tumor development;Discover Oncology;2024-09-11
2. History of trastuzumab: a case study in health technology reassessment and natural disinvestment in Veneto Region;Frontiers in Pharmacology;2024-08-06
3. Tumor-Targeted Oxaliplatin(IV) Prodrug Delivery Based on ROS-Regulated Cancer-Selective Glycan Labeling;Journal of Medicinal Chemistry;2024-05-13
4. Cáncer de mama en el norte del Perú: subtipos moleculares y HER2 low;Revista Peruana de Medicina Experimental y Salud Pública;2024-05-08
5. Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer;Breast Cancer Research and Treatment;2024-04-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3